BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30173878)

  • 1. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
    Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
    J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune checkpoint inhibitor-related cardiotoxicities].
    Zhou L; Li HW; Chen H
    Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):75-77. PubMed ID: 31887842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicities of novel cancer immunotherapies.
    Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
    Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
    Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
    Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 12. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
    Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
    Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
    Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitor-Associated Myocarditis.
    Ganatra S; Neilan TG
    Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Zhang L; Jones-O'Connor M; Awadalla M; Zlotoff DA; Thavendiranathan P; Groarke JD; Villani AC; Lyon AR; Neilan TG
    Curr Treat Options Cardiovasc Med; 2019 Jun; 21(7):32. PubMed ID: 31175469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
    Asnani A
    Curr Oncol Rep; 2018 Apr; 20(6):44. PubMed ID: 29644505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular toxicities associated with immune checkpoint inhibitors.
    Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
    Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
    Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.